COVID-19 News: BA.2.86 Spawns Such As JN.1, JN.1.1 And Recombinant Like XDD Increasing In Circulation Rapidly! Concerns Raised About Monovalent Jabs!
Nikhil Prasad Fact checked by:Thailand Medical News Team Dec 10, 2023 4 months, 2 weeks, 3 days, 1 hour, 5 minutes ago
Expect A Situation Worse Than During The Delta Surge In The Next Few Weeks. Hospitalizations And Deaths Expected To Rise Exponentially Along With Severe Long COVID Issues! Besides JN.1, Expect Sudden Emergence Of Other Fast Spreading Sub-lineages Of BA.2.86 and JN.1 That Are More Pathogenic. Surge Also Expected To Last For A Longer Period This Time Round!
COVID-19 News: When the hypermutated BA.2.86 variant was identified in mid-August 2023, many so called ‘experts’ said that that the BA.2.86 and its spawns are unlikely to be a threat and that it will unlikely spread.
https://edition.cnn.com/2023/09/03/health/covid-new-variant-pirola-early-lab-results/index.html
https://www.advisory.com/daily-briefing/2023/09/08/ba286-variant
https://www.ctvnews.ca/health/coronavirus/early-lab-tests-suggest-new-covid-19-variant-ba-2-86-may-be-less-contagious-and-less-immune-evasive-than-feared-1.6547033
https://www.medindia.net/news/new-covid-19-variants-ba286-and-eg51-not-a-threat-to-india
https://www.usatoday.com/story/news/health/2023/09/06/covid-19-variant-ba-2-86-vaccines/70772159007/
One study published in Nature journal even claimed that BA.2.86 variant had no potential to spread.
https://www.nature.com/articles/s41392-023-01712-0
Fast forward to day..unknown to most people the BA.2.86 variant has spawned more than 370 different kinds of sub-lineages of varying viral fitness, transmissibility and immune evasiveness with the most well-known ones being JN.1 JN.1.1, JN.2, JN.3, JN.1.2, etc.
https://cov-spectrum.org/collections/190
https://cov-spectrum.org/collections/189
https://cov-spectrum.org/collections/188
https://cov-spectrum.org/collections/169
(Note not all data can be found on CoV-spectrum as it is not updated timely, refer to GISAID to isolate such BA.2.86 sub-lineages)
It has even led to the emergence of a recombinant variant called XDD that involved the BA.2.86 and the EG.5.1.1 (An XBB Sub-lineage
).
https://github.com/sars-cov-2-variants/lineage-proposals/issues/1024
The JN.1 variant is not only spreading exponentially across the world and becoming the predominant circulating variant but many of the other BA.2.86 spawns are also slowly gaining a foothold!
In fact, the U.S. CDC has recently even admitted that the JN.1 variant could be the most transmissible variant to date and could also be the most immune evasive variant so far in its latest variant updates issued a few days ago.
https://www.cdc.gov/respiratory-viruses/whats-new/SARS-CoV-2-variant-JN.1.html
Many of the various agencies, ‘experts’ and corrupted mainstream media and news agencies under the direct or indirect payroll of the vaccine manufacturers and the WEF including the WHO, US,.CDC, ECDC had kept on advocating that the latest monovalent vaccine containing the XBB.1.5 spike proteins would be able to provide protection against the BA.2.86 variant and its spawns.
https://erictopol.substack.com/p/the-ba286-variant-and-the-new-booster
https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-says-updated-covid-vaccine-is-effective-against-newer-variant-2023-09-06/
https://health.ucdavis.edu/news/headlines/ba286-and-eg5-how-will-the-new-covid-19-boosters-work-with-new-variants-/2023/09
https://twitter.com/CDCgov/status/1733252642128748768
However, a Japanese study published in early December that was covered in a
COVID-19 News report in Thailand Medical News did warn that the XBB1.5 monovalent vaccine might not be effective against the BA.286 variant and its emerging spawns.
https://www.thailandmedical.news/news/breaking-covid-19-news-japanese-study-reveals-that-new-xbb-1-5-monovalent-vaccine-is-not-effective-against-circulating-sars-cov-2-variants
Many of the agencies like the WHO, U.S. CDC and also various other garbage health authorities and experts also kept on insisting that the BA.2.86 and its spawns are not driving disease severity despite data showing that where JN.1 is increasing in dominance of circulation, hospitalizations are also rising.
https://www.today.com/health/coronavirus/ba286-pirola-covid-variant-symptoms-rcna100944
https://www.cdc.gov/respiratory-viruses/whats-new/SARS-CoV-2-variant-JN.1.html
https://www.thailandmedical.news/news/breaking-covid-19-news-u-s-cdc-admits-that-jn-1-is-possibly-more-transmissible-as-infections-and-hospitalizations-rise-in-united-states
A latest study update by the same Japanese research lab that issued the warnings about the possibly ineffectiveness of the monovalent XBB.1.5 vaccine against the BA.2.86 variant but this time focusing on the JN.1 variant has indeed shown that the current XBB1.5 monovalent vaccine is unlikely to protect against the JN.1 variant and its emerging sub-lineages.
https://www.biorxiv.org/content/10.1101/2023.12.08.570782v1
https://twitter.com/SystemsVirology/status/1733661271445385626
Meanwhile preliminary data from studies underway that have yet to be published are showing that the JN.1 variant and its sub-lineages are better enhanced at utilizing the TMPRSS2 and ACE-2 receptors.
https://twitter.com/dronico/status/1731621226735415742
https://twitter.com/dronico/status/1732141782039966213
Case reports and studies underway are also showing that JN.1 and its newer sub-lineages are causing more serious lower respiratory infections and also affecting the gastrointestinal tract more.
Other studies underway show that it is also better adapt at using the NRP1 receptor hence possibly leading to better infections involving the brain and the CNS system. Yet another study underway shows that JN.1 and its newer sub-lineages can even use the bind to the nectin-1 & -2 & 3-O sulfated heparan sulfate (3-OS HS) receptors that are found in various ocular cell types!
Interestingly, we are seeing people infected with the JN.1 variant or its newer sub-lineages manifesting persistent coughs, chest pains, breathing issues, chronic fatigue and weakness headaches and body pains and vision issues along with abdominal issues, diarrhea and loss of appetite.
Some individuals do not express disease severity during initial stages of infections but develop other serious health issues later that required hospitalization. (This could be due to the fact that JN.1 and its newer sub-lineages are excellent at immune evasiveness and disarming the initial immune responses but still causing damage to various cells and cellular pathways.)
The JN.1 variant is now becoming predominant in various parts of the world including Singapore, France, Belgium, Denmark, Canada, Australia, the United States, Brazil etc.
https://www.thailandmedical.news/news/breaking-covid-19-news-the-jn-1-variant-now-accounts-for-60-percent-of-all-covid-19-cases-in-singapore-amidst-rising-covid-19-hospitalizations
https://twitter.com/theheraldsun/status/1732965732991042025
https://twitter.com/njasbech/status/1732691393498218594
https://twitter.com/juanitron777/status/1732553063775281428
https://twitter.com/AussieSteve6/status/1733726385561280572
https://twitter.com/RajlabN/status/1733734948404600940/photo/1
https://twitter.com/RajlabN/status/1730849022884147591
https://twitter.com/BarryHunt008/status/1733674290552172966
https://twitter.com/MarioNawfal/status/1733002625790923013
There are also speculation that the Mysterious White Lung Pneumonia seen in China and elsewhere and where Mycoplasma Pneumoniae has been blamed for it..... is actually caused by newer sub-lineages of JN.1, where they are not only causing lung damage but also causing rapid depletion of the immune system, paying the way for secondary opportunistic infections for the lungs including Mycoplasma Penumoniae, other fungus infections and even other viral and bacterial pathogens!
We can expect to see more fun in coming weeks but again note that we are expecting a very interesting announcement a few days before Christmas.
For the latest
COVID-19 News, keep on logging to Thailand Medical News.
Share
Tweet
Share
